Hospital Vithas La Salud
- Address
- lock Available on a paid plan
Neurology and Epilepsy Research
At Hospital Vithas La Salud, the Neurology department is actively involved in studies focused on nervous system diseases, especially focal epilepsy, refractory focal onset epilepsy, and adult focal seizures. The research is centered on evaluating new treatment options that may improve seizure control and help patients who continue to have seizures despite standard care.
- Testing new therapies for focal epilepsy and related seizure disorders
- Assessing safety and tolerability in adults with refractory epilepsy
- Measuring seizure reduction and treatment effectiveness
These trials reflect a strong interest in finding better ways to manage difficult-to-control epilepsy and improve daily outcomes for adults living with seizure disorders.
Oncology Research in Neoplasms
The site also contributes to research in oncology, with studies addressing metastatic castration-resistant prostate cancer. This work is aimed at comparing new treatment approaches with current physician-selected care to determine whether they can better delay disease progression and support improved cancer control.
- Evaluating treatment effectiveness in metastatic prostate cancer
- Comparing investigational therapy with standard clinician-chosen care
- Studying options for slowing cancer progression
Although the main focus at Hospital Vithas La Salud is neurology, this neoplasm research adds an important cancer-focused dimension to the site’s clinical trial portfolio.
Seizure Disorder Treatment Development
Several ongoing studies at the center are examining emerging medicines for focal onset seizures and primary generalized tonic-clonic seizures. The goal is to better understand how these therapies perform as add-on treatments, while also confirming their safety for adults already using standard anti-seizure medicines.
- Supporting treatment development for adult epilepsy
- Exploring add-on therapy for persistent seizures
- Building evidence on safety and tolerability in neurological disease
With multiple investigators involved, the research program shows sustained activity in epilepsy care and a continued effort to improve options for people whose seizures remain hard to control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Praxis Precision Medicines Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Praxis Precision Medicines Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Vithas La Salud
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects with Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1) | Takeda Development Center Americas Inc. | Phase II | Not Recruiting | Jul 2019 | Mar 2025 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bhv-7000 | 2 | Unknown | 2024-09-25 | 2024-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.